The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Neon Hospital
• Collaborator: Ondokuz Mayıs University
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Having diffuse diabetic macular edema persisted at least 1 month

• No intravitreal injection in last 3 months.

• No retinal laser photocoagulation in last 6 months

• Not have any other macular disease causing macular edema

Exclusion Criteria:

• Having ischemic macula

• Intravitreal injection in last 3 months.

• Retinal laser photocoagulation in last 6 months

• Have any other macular disease causing macular edema